Rev Pneumol Clin
-
We report the case of a 35-year-old woman in whom a systematic thoracic x-ray led to the diagnosis of unilateral hyperlucent lung due to a carcinoid tumor obstructing the main left bronchus almost completely. Injected computed tomography permitted diagnosis of left lung hypoperfusion and visualization of the tumor. After enlarged inferior left lobar resection, normal perfusion was observed six months later on the isotopic lung perfusion scan. Other reported causes of unilateral hyperlucent lung are discussed as well as pathophysiological mechanisms of lung hypoperfusion and hypoxic vasoconstriction.
-
Review
[What are the questions concerning small cell lung cancer? How should research be orientated?].
Spectacular therapeutic progress for small cell lung cancer was obtained some thirty years ago with the introduction of polychemotherapy. Since when, except that which concerns radio-chemotherapy in the limited forms, the development of treatments has been relatively poor. Based on the analysis of published literature, the aim of this review is to discuss the research routes. The problems can be summarised in eleven principle axes: identification of new active drugs, development of new combinations with new chemotherapeutic agents, the place of analogs, the role of thoracic surgery, optimal radio-chemotherapeutic regimens, intensity of chemotherapy, the place of haematological growth factors, the duration of chemotherapy and maintenance treatments, biological treatments, prevention and treatment of cerebral metastases and salvage chemotherapy.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
[Efficacy and acceptability of the fixed fluticasone + salmeterol combination in the treatment of acute asthma attacks. Results of a one-year comparative study].
The objective of an asthma treatment is to control asthma, particularly to prevent exacerbations. ⋯ The fixed fluticasone/salmeterol combination provided a protection as good as that obtained with free combinations over a one-year treatment period, with a significant improvement in treatment acceptability and a good clinical safety.